본문 바로가기
KERD
논문KCI 등재

갈란타민(Galantamine) 투여 후 순수 알츠하이머병 치매와 혼합성 치매 환자의 주의력, 일상생활능력 및 신경정신행동 증상에 대한 효과 평가

Effects of Galantamine Treatment on Attention, Activities of Daily Living, and Neuropsychiatric Symptoms between the Patients with Pure Alzheimer’s Disease and Mixed Dementia

김도관|이영민|김혜란|윤지혜|문유진|안인숙|황태영|강효신
대한노인정신의학회 (Korean Association For Geriatric Psychiatry)|2012.06|노인정신의학 (Journal of Korean Geriatric Psychiatry)|제16권 제1호|pp. 24-30|DOI http://dx.doi.org/

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

치료 효과주의력Alzheimer’s diseaseAttention알츠하이머병 치매혼합성 치매갈란타민Mixed dementiaGalantamineClinical efficacy.

초록

Objectives:The purpose of this study was to compare the efficacy of galantamine treatment, especially attention ability between patients with pure Alzheimer’s disease (AD) and Mixed dementia (MD) during a 24-week trial. Methods:A total of 40 patients were recruited for this 24-week study. The effect of galantamine on attention was measured us- ing Seoul Computerized NeuroCognitive Function Test (SCNT) and frontal functions test of Seoul Neuropsychological Screening Battery (SNSB). Patients’activities of daily living using the Seoul-Activities of Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily Living (S-IADL) ; behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline and 24-week. Results:17 pure AD patients and 23 MD patients were analyzed in this study. Attention as measured by SCNT was not signifi- cantly different from baseline after 24 weeks of treatment in both groups. There was no significant difference between two groups in mean change from baseline in the SCNT, S-ADL, S-IADL and K-NPI scores at 24-week. Conclusion:Galantamine showed a therapeutic effect on cognition, activities of daily living, neuropsychiatric symptoms in pure AD and MD. Furthermore, Galantamine may specifically help to maintain attention and it may have positive effects on other cognitive and functional abilities.

Abstract

Objectives:The purpose of this study was to compare the efficacy of galantamine treatment, especially attention ability between patients with pure Alzheimer’s disease (AD) and Mixed dementia (MD) during a 24-week trial. Methods:A total of 40 patients were recruited for this 24-week study. The effect of galantamine on attention was measured us- ing Seoul Computerized NeuroCognitive Function Test (SCNT) and frontal functions test of Seoul Neuropsychological Screening Battery (SNSB). Patients’activities of daily living using the Seoul-Activities of Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily Living (S-IADL) ; behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline and 24-week. Results:17 pure AD patients and 23 MD patients were analyzed in this study. Attention as measured by SCNT was not signifi- cantly different from baseline after 24 weeks of treatment in both groups. There was no significant difference between two groups in mean change from baseline in the SCNT, S-ADL, S-IADL and K-NPI scores at 24-week. Conclusion:Galantamine showed a therapeutic effect on cognition, activities of daily living, neuropsychiatric symptoms in pure AD and MD. Furthermore, Galantamine may specifically help to maintain attention and it may have positive effects on other cognitive and functional abilities.

참고문헌 (27)

  1. Doody RS, "Practice parameter: Management of dementia (an evidence-based review)", Neurology, 56, pp.1154~1166 (2001)
  2. Lilienfeld S, "Galantamine: additional benefits to patients with Alzheimer’s disease", Dement Geriatr Cogn Disord, 11(Sup-pl 1), pp.19~27 (2000)
  3. Jones GM, "Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease", Psychopharmacology, 108, pp.485~494 (1992)
  4. Dani JA, "Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system", Annu Rev Pharmacol Toxicol, 47, pp.699~729 (2007)
  5. Galvin JE, "Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil", Alzheimer Dis Assoc Disord, 22, pp.30~38 (2008)
  6. Raskind MA, "Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group", Neurology, 54, pp.2241~2248 (2000)
  7. Tariot PN, "5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group", Neurology, 54, pp.2249~2276 (2000)
  8. Wilcock GK, "Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group", BMJ, 321, pp.1445~1449 (2000)
  9. Erkinjuntti T, "Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial", Lancet, 359, pp.1283~1290 (2002)
  10. Thavichachart N, "Efficacy study of ga-lantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-ti-tration regimen", Int J Clin Pract, 60, pp.533~540 (2006)
  11. Zekry D, "Mixed dementia: Epidemiology, diagnosis, and treatment", J Am Geriatr Soc, 50, pp.1431~1438 (2002)
  12. McKhann G, "Clinical diagnosis of Alzheime’s disease", Neurology, 34, pp.939~944 (1984)
  13. Kang YW, "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
  14. Fazekas F, "MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging", Am J Roentgenol, 149, pp.351~356 (1987)
  15. Hachinski VC, "Cerebral blood flow in dementia", Arch Neurol, 32, pp.632~637 (1975)
  16. Kang Y, "Seoul Neuropsychological Screening Battery (SNSB)" (2003), Human Brain Research & Consulting Co
  17. Ku HM, "A stu-dy on the reliability and validity of Seoul-Activities of Daily Living (S-ADL)", J Korean Geriatr Soc, 8, pp.206~214 (2004)
  18. 구형모, "일상활동평가-복합(Seoul-Instrumental Activities of Daily Living ; S-IADL)의 신뢰도 및 타당도 연구", 신경정신의학, 43(2), pp.189~199 (2004), 대한신경정신의학회
  19. Cummings JI, "The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia", Neurology, 44, pp.2308~2314 (1994)
  20. Choi SH, "The Korean version of the neuropsychiatric inventory: A scoring tool for neuropsychiatric disturbance in dementia patients", J Korean Med Sci, 15, pp.609~615 (2000)
  21. Vellas B, "Early onset effects of galantamine treatment on attention in patients with Alzheimer’s disease", Curr Med Res Opin, 21, pp.1423~1429 (2005)
  22. Gorus E, "The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients", J Clin Psychopharmacol, 27, pp.182~187 (2007)
  23. Galasko D, "Galanta-mine maintains ability to perform activities of daily living in patients with Alzheimer’s disease", J Am Geriatr Soc, 52, pp.1070~1076 (2004)
  24. Gauthier S, "Efficacy of donepezil on behavioral symptoms in patients with moderate-to-severe Alzheimer’s disease", Int Psychogeriatr, 14, pp.389~404 (2002)
  25. Bullock R, "GAL-INT-6 Study Group. Management of patients with Alzheimer’s disease plus cerebrovascular disease: 12-month treatment with galantamine", Dement Geriatr Cogn Disord, 17, pp.29~34 (2004)
  26. Winblad B, "Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success", Int J Geriatr Psychiatry, 16, pp.653~666 (2001)
  27. Zekry D, "Management of mixed dementia", Drugs Aging, 27, pp.715~728 (2010)

관련 논문AI추천

순수 알츠하이머병 치매 환자군과 혼합성 치매 환자군에서 12개월간의 도네페질(Donepezil) 투여에 따른 치료 성적의 비교 평가강효신, 김도관, 김혜란, 문유진, 안인숙, 윤지혜, 이영민, 정재원, 황태영대한노인정신의학회 · 노인정신의학2010 · 제14권 제1호Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer’s Dementia after Failure to Respond to Donepezil황태영, Doh Kwan Kim, Inn Sook Ahn, Seonwoo Kim대한신경정신의학회 · PSYCHIATRY INVESTIGATION2016 · 제13권 제3호알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가： 12개월 추적관찰 연구강효신, 김도관, 김혜란, 문유진, 안인숙, 윤지혜, 이영민, 정재원, 황태영대한노인정신의학회 · 노인정신의학2010 · 제14권 제2호The Effects of Galantamine Treatment on Attention and Its Relationship with Cognition and Activities of Daily Living in Patients with Mild to Moderate Alzheimer’s Disease김범준, 나덕렬, 박종무, 배희준, 이재홍, 정지향, 차경렬, 한설희, 홍윤정대한신경과학회 · Journal of Clinical Neurology2015 · 제11권 제1호알츠하이머병에서 아세틸콜린에스테라제 억제제에 대한 치료 반응과 관련된 요인김정란, 이미지, 한송이대한생물치료정신의학회 · 생물치료정신의학2015 · 제21권 제2호아세틸콜린에스테라제 억제제를 투여받는 알츠하이머병 환자에서 정신행동증상에 대한 콜린 알포세레이트 병용 치료의 효과김현, 이강준대한노인정신의학회 · 노인정신의학2025 · 제29권 제2호

이 간행물의 다른 논문 (7건)

알츠하이머병의 진단 기준연병길, 홍나래pp. 3-6새로운 알츠하이머병 임상진단기준 : NIA-AA 진단가이드라인을 중심으로이동영, 손보경pp. 7-12ADNI 연구에서 알츠하이머병 및 경도인지장애의 뇌영상 표지자이준영pp. 13-16뇌척수액과 말초혈액 내 알츠하이머병의 생화학적 생체표지자김어수, 이영민, 최원정, 박민선pp. 17-23알츠하이머 치매 환자에서 교육 수준과 우울증의 연관성 : CREDOS(Clinical Research Center for Dementia of South Korea) 연구의 결과이재홍, 강효신, 나덕렬, 김도관, 김상윤, 김성윤, 이유진, 최성혜, 김상하, 윤혜연, 명우재, 임신원, 송지혜, 최준배, 한설희pp. 31-37
원문 보기